A novel class of in vivo active anticancer agents: Achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065

Journal of Medicinal Chemistry

Volumn 48, Issue 11, 2005, Pages 3903-3918

  Sato, Atsushi ^a,c   McNulty, LuAnne ^a   Cox, Kari ^a   Kim, Susan ^a   Scott, Adrienne ^a   Daniell, Kristen ^a   Summerville, Kaitlin ^a   Price, Carly ^a   Hudson, Stephen ^a   Kiakos, Konstantinos ^b   Hartley, John A ^b   Asao, Tetsuji ^c   Lee, Moses ^a  

^a FURMAN UNIVERSITY   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,9,9A TETRAHYDROPROPA[C]BENZO[E]INDOL 4 ONE; 2 [4 AMINO 2 (5,6,7 TRIMETHOXYINDOLE 2 CARBOXAMIDO)NAPHTHALEN 1 YL]ETHANOL; 2 [4 AMINO 2 (5,6,7 TRIMETHOXYINDOLE 2 CARBOXAMIDO)NAPHTHALEN 1 YL]ETHYL ACETATE; 4 (2 CHLOROETHYL) 3 (3 AZA 2,4 DIMETHOXYCINNAMOYLAMIDO) 1 NAPHTHYLAMINE; 4 (2 CHLOROETHYL) 3 (3 AZA 4 METHOXYCINNAMOYLAMIDO) 1 NAPHTHYLAMINE; 4 (2 CHLOROETHYL) 3 (5 METHOXYINDOLE 2 CARBOXAMIDO) 1 NAPHTHYLAMINE; 4 (2 CHLOROETHYL) 3 (5,6,7 TRIMETHOXYINDOLE 2 CARBOXAMIDO) 1 NAPHTHOL; 4 (2 CHLOROETHYL) 3 (5,6,7 TRIMETHOXYINDOLYL 2 CARBOXAMIDO) 1 NAPHTHYLAMINE; 4 (2 CHLOROETHYL) 3 [5 (5 BENZOFURAN 2 CARBOXAMIDO)INDOLE 2 CARBOXAMIDO] 1 NAPHTHYLAMINE; ADOZELESIN; ANTINEOPLASTIC AGENT; CYCLOPROPANE DERIVATIVE; DUOCARMYCIN DERIVATIVE; INDOLE DERIVATIVE; RACHELMYCIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CHIRALITY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DOSE RESPONSE; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; KIDNEY CANCER; LUNG CANCER; MELANOMA; MOUSE; NONHUMAN; OVARY CANCER; RACEMIC MIXTURE; SCID MOUSE; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; XENOGRAFT;

1-NAPHTHYLAMINE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYCLOPROPANES; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INDOLE ALKALOIDS; INDOLES; MICE; MICE, INBRED C57BL; MICE, SCID; NAPHTHALENES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 20144380099     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050179u     Document Type: Article

References (66)

1. (a) Advances in DNA Sequence Specific Agents; Jones, G. B., Palumbo, M., Eds.; JAI Press Inc.; Greenwich, CT, 1998; Vol. 3.
2. (b) Li, L. H.; Wallace, T. L.; DeKoning, T. F.; Warpehoski, M. A.; Kelly, R. C.; Prairie, M. D.; Drueger, W. C. Structure and Activity Relationship of Several Novel CC-1065 Analogs. Invest. New Drugs 1987, 5, 329-337.
3. (c) Li, L. H.; Kelly, R. C.; Warpehoski, M. A.; McGovern, J. P.; Gebhard, I.; DeKoning, T. F. Adozelesin, a Selected Lead among Cyclopropylpyrroloindole Analogs of the DNA-Binding Antibiotic, CC-1065. Invest. New Drugs 1991, 9,137-148.
4. (d) Warpehoski, M. The DNA Sequence Selectivity of CC-1065. In Advances in DNA Sequence Specific Agents; Hurley, L. H., Ed.; JAI Press: Greenwich, CT, 1992; Vol. 1, pp 217-245.
5. (a) Boger, D. L.; Johnson, D. S. CC-1065 and the Duocarmycins; Understanding their Biological Function through Mechanistic Studies. Angew. Chem., Int. Ed. Engl. 1996, 35, 1438-1474.
6. (b) Boger, D. L.; Johnson, D. S. CC-1065 and the Duocarmycins: Unraveling the Keys to a New Class of Natural Derived DNA Alkylating Agents. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 3642-3649.
7. (a) Boger, D. L. The Duocarmycins: Synthetic and Mechanistic Studies. Acc. Chem. Res. 1995, 28, 20-29.
8. (b) Boger, D. L. Duocarmycins: A New Class of Sequence Selective DNA Minor Groove Alkylating Agents. Chemtracts: Org. Chem. 1991, 4, 329-349.
9. (a) Hanka, L. J.; Dietz, A.; Gerpheide, S. A.; Kuentzel, S. L.; Martin, D. G. CC-1065 (NSC-298223), a New Antitumor Antibiotic. Production in-vivo Biological Activity, Microbiological Assays, and Taxonomy of the Producing Microorganism. J. Antibiot. 1978, 31, 1211-1217.
10. (b) McGovern, J. P.; Clarke, G. L.; Pratte, E. A.; DeKoning, T. F. Preliminary Toxicity Studies with the DNA-Binding Antibiotic, CC-1065 J. Antibiot. 1983, 37, 63-70.
11. (c) Warpehoski, M. A.; Gebhard, J.; Kelly, R. C.; Krueger, W. C.; Li, L. H.; McGovern, J. P. Stereoelectronic Factors Influencing the Biological Activity and DNA Interaction of Synthetic Antitumor Agents Modeled on CC-1065. J. Med. Chem. 1988, 31, 590-603.
12. (a) Ichimura, H.; Ogawa, T.; Takahashi, K.; Kobayashi, E.; Kawamoto, I.; Yasuzawa, T.; Takahashi, I.; Nakano, H. Duocarmycin SA, A New Antibiotic from Streptomyces sp. J. Antibiot. 1990, 43, 1037-1038.
13. (b) Yaszawa, T.; Saitoh, Y.; Ichimura, M.; Takahashi, I.; Sano, H. Structure of Duocarmycin SA, A Potent Antitumor Antibiotic. J. Antibiot. 1991, 44, 445-447.
14. (c) Yasuzawa, T.; Muroi, K.; Ichimura, M.; Takahashi, I.; Ogawa, T.; Takahashi, K.; Sano, H.; Saitoh, Y. Duocarmycins, Potent Antitumor Antibiotics by Streptomyces sp. Structures and Chemistry. Chem. Pharm. Bull. 1995, 43, 378-391.
15. (d) Ichimura, M.; Ogawa, T.; Takahashi, K.; Mihara, A.; Takahashi, I.; Nakano, H. Interconversion and Stability of Duocarmycins, a New Family of Antitumor Antibiotics: Correlation to Their Cytotoxic and Antimicrobial Activities In-vitro. Oncol. Res. 1993, 5, 165-171.
16. (e) Gomi, K.; Kobayashi, E.; Miyoshi, K.; Ashizawa, T.; Okamoto, A.; Ogawa, T.; Katsumata, S.; Mihara, A.; Okabe, M.; Hirata, T. Anticellular and Antitumor Activity of Duocarmycins. Jpn. J. Cancer Res. 1992, 83, 113-120.
17. Hurley, L. H.; Reynolds, V. S.; Swenson, D. H.; Petzold, G. L.; Scahill, T. A. Reaction of the Antitumor Antibiotic CC-1065 with DNA: Structure of a DNA Adduct with DNA Sequence Specificity. Science 1984, 226, 843-844.
18. Boger, D. L.; Johnson, D. S.; Yun, W. (+)- and ent-(-)-Duocarmycin SA and (+)- and ent-(-)-N-BOC-DSA DNA Alkylation Properties. Alkylation Site Models that Accomodate the Offset AT-Rich Adenine N3 Alkylation Selectivity of the Enantiomeric Agents. J. Am. Chem. Soc. 1994, 116, 1635-1656.
19. Reynolds, V. L.; Molineux, I. J.; Kaplan, D. J.; Swenson, D. H.; Hurley, L. H. Reaction of the Antitumor Antibiotic CC-1065 with DNA Location of the Site of Thermally Induced Strand Breakage and Analysis of DNA Sequence Specificity. Biochemistry 1985, 24, 6228-6237.
20. (a) Hightower, R. D.; Sevin, B. U.; Pevras, J. P.; Untch, M.; Angioli, R.; Averette, H. In-Vitro Evaluation of the Novel Chemotherapeutic Agents U-73975, U-77779, and U-80244. Gynecol. Oncol. 1992, 42, 186-190.
21. (b) Cote, S.; Momparler, R. L. Evaluation of the Antineoplastic Activity of Adozelesin Alone and in Combination with 5-Aza-2′-deoxycytidine and Cytosine Arabinoside on DLD-1 Human Colon Carcinoma Cells. Anti-Cancer Drugs 1993, 4, 327-333.
22. (c) Fleming, G. F.; Ratain, S. M.; O'Brien, R. L.; Schilsky, P. C.; Ramos, R.; Richards, J. M.; Vogelzang, N. J.; Kasunic, D. A.; Earhart, R. H. Phase I Study of Adozelesin Administered by 24-Hour Continuous Intravenous Infusion. J. Natl. Cancer Inst. 1994, 86, 368-372.
23. (d) Foster, B. J.; Larusso, P. M.; Poplin, E.; Zalupski, M.; Valdivieso, M.; Wozniak, A.; Flaherty, L.; Kasunic, D. A.; Earhart, R. H.; Baker, L. H. Phase I Trial of Adozelesin Using the Treatment Schedule of Daily ×5 Every 3 Weeks. Invest. New Drugs 1996, 13, 321-326.
24. (e) Burris, H.; Earhart, R.; Kuhn, J.; Shaffer, D.; Smith, L.; Weiss, G.; Kusanic, D.; Radbury, G.; Campbell, L.; Von Hoff, D. A Phase I Trial of Adozelesin, a Novel DNA Sequence-Specific Alkylating Agent. Proc. Am. Assoc. Cancer Res. 1992, 33, 265.
25. (f) Burris, H. A.; Dleras, V. C.; Tunca, M.; Earhart, R. H.; Eckardt, J. R.; Rodriguez, G. I.; Shaffer, D. S.; Fields, S. M.; Campbell, E.; Scaaf, L.; Kasunic, D.; Von Hoff, D. D. Phase I Study with the DNA Sequence Specific Agent Adozelesin. Anticancer Drugs 1997, 8, 588-596.
26. (g) Foster, B. J.; LoRusso, P. M.; Poplin, E.; Zalupski, M.; Valdivieso, M.; Wozniak, A.; Flaherty, L.; Kasunic, D. A.; Earhart, R. H.; Baker, L. H. Phase I Trial of Adozelesin using the Treatment Schedule of Daily ×5 Every 3 Weeks. Invest. New Drugs 1996, 13, 321-326.
27. (a) Li, L. H.; Dekoning, J. F.; Kelly R. C.; Krueger, W. C.; McGovern, J. P.; Padbury, G. E.; Petzold, G. L.; Wallace, T. L.; Ouding, R. J.; Praire, M. D.; Gebhard, I. Cytotoxicity and Antitumor Activity of Carzelesin, a Prodrug Cyclopropyrroloindole Analogue. Cancer Res. 1992, 52, 4904-4913.
28. (b) van Telligen, O.; Punt, C. J. A.; Awada, A.; Wagener, D. J. T.; Piccart, M. J.; Groot, Y.; Scaaf, L. J.; Henrar, R. E. C. Nooijen, W. J.; Beijnen, J. H. A Clinical Pharmacokinetics Study of Carzelesin Given by ShortOLINIT-Term Intravenous Infusion in a Phase I Study. Cancer Chemomther. Pharmacol. 1998, 41, 377-384.
29. (a) Walker, D. L.; Reid, F. M.; Ames, M. M. Preclinical Pharmacology of Bizelesin, a Potent Bifunctional Analog of the DNA-Binding Antibiotic CC-1065. Cancer Chemother. Pharmacol. 1994, 34, 317-322.
30. (b) Volpe, D. A.; Tomaszewski, J. E.; Parchment, R. E.; Garg, A.; Flora, K. P.; Murphy, M. J.; Grieshaber, C. K. Myelotoxic Effects of the Bifunctional Alkylating Agent Bizelesin on Human, Canine and Murine Myeloid Progenitor Cells. Cancer. Chemother. Pharmacol. 1996, 39, 143-149.
31. (c) Pitot, H. C.IV; Erlichman, C.; Reid, J. M.; Sloan, J. A.; Ames, M. M.; Bagniewski, P. G.; Atherton-Skaff, P.; Adjei, A. A.; Rubin, J.; Rayson, D.; Goldberg, R. M. A Phase I Study of Bizelesin (NSC615291) in Solid Tumors. Proc. Am. Assoc. Cancer Res. 1999, 40, 91.
32. (a) Nagamura, S.; Kobayashi, E.; Gomi, K.; Saito, H. Studies on the Active Metabolite (DU-86) of KW-2189, A Novel Derivative of Duocarmycin. Bioorg. Med. Chem. Lett. 1996, 6, 2147-2150, and references therein,
33. (b) Alberts, S. R.; Erlichman, C.; Reid, J. M.; Ames, M. M.; Sloan, J. A.; Richardson, R. L. Phase I Trial of KW2189 in Solid Tumors Using a 50 Day Administration Schedule. Proc. Am. Assoc. Cancer Res. 1996, 37, 393.
34. (c) Abbruzzese, J. L.; Madden, T.; Newman, R. A. Phase I Clinical and Pharmacokinetic Trial of KW2189. Proc. Am. Assoc. Cancer Res. 1996, 37, 165.
35. (d) Niitani, H.; Horikoshi, N.; Hasegawa, K.; Fukuoka, M.; Kudoh, S.; Hino, M. Phase I study of KW2189, a Derivative of New Anticancer Antibiotic Duocarmycin. Proc. Am. Assoc. Cancer Res. 1995, 36, 243.
36. (e) Amishiro, N.; Nagamura, S.; Murakata, C.; Okamoto, A.; Kobayashi, E.; Asada, M.; Gomi, K; Tamaoki, T.; Okabe, M.; Yamaguchi, N.; Yamaguchi, K.; Saito, H. Synthesis and Antitumor Activity of Duocarmycin Derivatives: Modification at C-8 position of A-ring Pyrrole Compounds Bearing the Simplified DNA-Binding Groups. Bioorg. Med. Chem. 2000, 8, 381-391.
37. (f) Asai, A.; Nagamura, S.; Kobayashi, E.; Gomi, K.; Saito, H. Synthesis and Antitumor Activity of Water-Soluble Duocarmycin B1 Prodrugs. Bioorg. Med. Chem. Lett. 1999, 9, 2995-2998.
38. Boger, D. L.; McKie, J. A.; Han, N.; Tarbie, C. M.; Riggs, H. W.; Kitos, P. A. The Hammett Correlation for CC-1065 and Duocarmycin Analogs: Magnitude of Substituent Electronic Effects on Functional Reactivity. Bioorg. Med. Chem. Lett. 1996, 6, 659, and references therein.
39. (a) Boger, D. L.; McKie, J. A. An Efficient Synthesis of 1, 2, 9, 9a-Tetrahydropropa[c]benzo[e]indol-4-one (CBI): An Enhanced and Simplified Analog of the CC-1065 and Duocarmycin Alkylation Subunits. J. Org. Chem. 1995, 60, 1271-1275.
40. (b) Boger, D. L.; Yun, W.; Han, N. 1,2,9,9a-Tetrahydrocyclopropa[c]benz- [e]indol-4-one (CBI) Analogs of CC-1065 and the Duocarmycins: Synthesis and Evaluation. Bioorg. Med. Chem. 1995, 3, 1429-1453.
41. (c) Aristoff, P. A.; Johnson, P. D. Synthesis of CBI-PDE-I Dimer, the Benzannelated Analogue of CC-1065. J. Org. Chem. 1992, 57, 6234-6239.
42. Baraldi, P. G.; Cacciari, B.; Pinedo de las Infantas, M. J.; Romagnoli, R.; Spatullo, G.; Cozzi, P.; Mongelli, N. Synthesis, Chemical Solvolytic Stability and Preliminary Biological Evaluation of (±)-N-BOC-CPzI: A Pyrazole Analog of the Left-Hand Segment of the Antitumor Agent CC-1065. Anti-Cancer Drug Design 1997, 12, 67-74.
43. Mohamadi, F.; Spees, M. M.; Staten, G. S.; Marder, P.; Kipka, J. K.; Johnson, D. A. Total Synthesis and Biological Properties of Novel Antineoplastic (Chloromethyl)furanoindolines: An Asymmetric Hydroboraton Method Synthesis of the Alkylation Subunits. J. Med. Chem. 1994, 37, 232-239.
44. 32P-End Labeled Double-Stranded DNA for Binding Studies: Development of a Protocol for Examination of Functional Features of (+)-CC-1065 and the Duocarmycins that Contribute to Their Sequence-Selective DNA Alkylation Properties. Tetrahedron 1991, 47, 2661-2682.
45. (b) Boger, D. L.; Ishizaki, T.; Zarrinmayeh, H.; Munk, S. A.; Kitos, P. A.; Suntorwart, O. Duocarmycin-Pyrindamycin DNA Alkylation Properties and Identification, Synthesis, and Evaluation of Agents Incorporating the Pharmacophore of the Duocarmycin-Pyrindamycin Alkylation Subunit. Identification of the CC-1065-Duocarmycin Common Chromophore. J. Am. Chem. Soc. 1990, 112, 8961-8971.
46. (a) Atwell, G. J.; Tercel, M.; Boyd, M.; Wilson, W. R.; Denny, W. A. Synthesis and Cytotoxicity of 5-Amino-1-(chloromethyl)-3-[(5,6,7- trimethoxyindol-2-yl)carbonyl]-1,2-dihydro-3if'-benz[e]indole (Amino-seco-CBI-TMI) and Related 5-Alkylamino Analogues: New DNA Minor Groove Alkylating Agents. J. Org. Chem. 1998, 63, 9414-9420.
47. (b) Atwell, G. J.; Milbank, J. J. B.; Wilson, W. R.; Hogg, A.; Denny, W. A. 5-Amino-1-(chloromethyl)-1,2-dihydro-3H-benz[e]indoles: Relationships between Structure and Cytotoxicity for Analogues Bearing Different DNA Minor Groove Binding Subunits. J. Med. Chem. 1999, 42, 3400-3411.
48. (c) Tercel, M.; Gieseg, M. A.; Denny, W. A.; Wilson, W. R. Synthesis and Cytotoxicity of Amino-Seco-DSA: An Amino Analogue of the DNA Alkylating Agent Duocarmycin SA. J. Org. Chem. 1999, 64, 5946-5953.
49. Howard, T. T.; Lingerfelt, B. M.; Purnell, B. L.; Scott, A. E.; Price, C. A.; Townes, H. M.; McNulty, L.; Handl, H. L.; Summerville, K; Hudson, S. J.; Bowen, P. J.; Kiakos, K; Hartley, J. A.; Lee, M. Novel Furano Analogs of Duocarmycin C1 and C2: Design, Synthesis and Biological Evaluation of seco-iso-Cyclopropyl-furano[e]indoline (seco-iso-CFI) and the Unexpected seco-Cyclopropyltetrahydrofurano[f]quinoline (seco-CFQ) Analogs. Bioorg. Med. Chem. 2002, 10, 2941-2952.
50. Kupchinsky, S.; Centioni, S.; Howard, T.; Trzupek, J.; Roller, S.; Carnahan, V.; Townes, H.; Purnell, B.; Price, C.; Handl, H.; Summerville, K.; Johnson, K.; Toth, J.; Hudson, S.; Kiakos, K.; Hartley, J. A.; Lee, M. Novel Class of Achiral seco-Analogs of CC-1065 and the Duocarmycins: Design, Synthesis, DNA Binding, and Anticancer Properties. Bioorg. Med. Chem. 2004, 12, 6221-6236.
51. Toth, J. L.; Trzupek, J. D.; Flores, L. V.; Kiakos, K.; Hartley, J. A.; Pennington, W. T.; Lee, M. A Novel Aohiral seco-Amino-Cyclopropylindoline (CI) Analog of CC-1065 and the Duocarmycins: Design, Synthesis and Biological Studies. Med. Chem. 2005, 1, 13-19.
52. (a) Daniell, K.; Stewart, M.; Madsen, E.; Le, M.; Handl, H.; Brooks, N.; Kiakos, K.; Hartley, J. A.; Lee, M. Design, Synthesis and Biological Evaluation of Achiral Analogs of Duocarmycin SA.Bioorg. Med. Chem. Lett. 2005, 15, 177-180.
53. (b) Fukuda, Y.; Oomori, Y.; Kusama, T.; Terashima, S. Bioorg. Med. Chem. Lett. 1997, 7, 749-752.
54. (a) Talen, H. W. Rec. The Replaceability of the Halogen Atom in 1-Chloro-2,4-dinitro- and -2,4,5-Trinitronaphthalenes. Trav. Chim. 1928, 47, 329-345.
55. (b) Ullmann, F.; Brück, W. 1,2-Dinitro-α-naphthol. Ber. 1908, 41, 3932-3939.
56. Amishiro, N.; Nagamura, S.; Kobayashi, E.; Gomi, K.; Saito, H. New Water-Soluble Duocarmycin Derivatives: Synthesis and Antitumor Activity of A-ring Pyrrole Compounds Bearing β-Heteroarylacryloyl Groups. J. Med. Chem. 1999, 42, 669-676.
57. Ponti, M.; Forrow, S. M.; Souhami, R. L.; D'Incalci, M.; Hartley, J. A. Measurement of the Sequence Specificity of Covalent DNA Modification by Antineoplastic Agents Using Taq DNA Polymerase. Nucl. Acids Res. 1991, 19, 2929-2933.
58. Carmichael, J.; DeGraff, W. G.; Gadzar, A. F.; Minna, J. D.; Mitchell, J. B.; Evaluation of a Tetrazolium-based Semi-automated Colorimetric Assay: Assessment of Chemosensitivity Testing. Cancer Res. 1987, 47, 936-946.
59. (a) Boger, D. L.; Yun, W. CBI-TMI: Synthesis And Evaluation of a Key Analog of the Duocarmycins. Validation of a Direct Relationship Between Chemical Solvolytic Stability and Cytotoxic Potency and Confirmation of the Structural Features Responsible for the Distinguishing Behavior of Enantiomeric Pairs of Agents. J. Am. Chem. Soc. 1994, 116, 7996-8006.
60. (b) Atwell, G. J.; Wilson, W. R.; Denny, W. A. Synthesis and Cytotoxicity of Amino Analogues of the Potent DNA Alkylating Agent Seco-CBI-TMI. Bioorg. Med. Chem. Lett. 1997, 7, 1493-1496.
61. Boyd, R. B. Status of the NCI Preclinical Antitumor Drug Discovery Screen. Principles Practices Oncol. 1989, 3, 1-12.
62. (a) Wrasidlo, W.; Johnson, D. S.; Boger, D. L. Induction of Endonucleolytic DNA Fragmentation and Apoptosis by the Duocarmycins. Bioorg. Med. Chem. Lett. 1994, 4, 631-636.
63. (b) Wang, Y.; Yuan, H.; Ye, W.; Wright, S. C.; Wang, H.; Larrick, J. W. Synthesis and Preliminary Biological Evaluations of CC-1065 Analogues: Effects of Different Linkers and Terminal Amides on Biological Activity. J. Med. Chem. 2000, 43, 1541-1549.
64. Pecere, T.; Gazzola, M. V.; Mucignat, C.; Parolin, C.; Vecchia, F. D.; Cavaggioni, A.; Basso, G.; Diaspro, A.; Salvato, B.; Carli, M.; Palu, G. Aloe-Emodin is a New Type of Anticancer Agent with Selective Activity Against Neuroectodermal Tumors. Cancer Res. 2000, 60, 2800-2804.
65. Li, L. H.; Kelley, R. C.; Warpehoski, M. A.; McGovern, J. P.; Gebhard, I.; DeKoning, T. F. Adozelesin, a Selected Lead Among Cyclopropylindole Analogs of the DNA-Binding Antibiotic, CC-1065. Invest. New Drugs 1991, 9, 137.
66. Boyd, R. B. The NCI In Vitro Anticancer Drug Discovery Screen. In Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval; Teicher, B., Ed.; Humana Press Inc.: Totowa, NJ, 1997; pp 23-42.